CRSP
Crispr Therapeutics AGNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.89B
P/E Ratio
—
EPS
$-6.47
Beta
1.79
52W High
$78.48
52W Low
$33.03
50-Day MA
$52.55
200-Day MA
$56.48
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
23.36
PEG Ratio
-0.21
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Fundamentals
| Revenue (TTM) | $3.51M |
| Gross Profit (TTM) | $-494.78M |
| EBITDA | $-548.84M |
| Operating Margin | -17912.00% |
| Return on Equity | -30.20% |
| Return on Assets | -15.80% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $20.04 |
| Price-to-Book | 2.54 |
| Price-to-Sales (TTM) | 1393.19 |
| EV/Revenue | 84.52 |
| EV/EBITDA | 14.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -97.60% |
| Shares Outstanding | $96.43M |
| Float | $95.56M |
| % Insiders | 5.90% |
| % Institutions | 73.00% |
Historical Volatility
HV 10-Day
76.91%
HV 20-Day
64.06%
HV 30-Day
60.42%
HV 60-Day
66.55%
HV Rank
44.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($83.35 target)
5
Strong Buy12
Buy9
Hold1
SellData last updated: 4/30/2026